Alignment Healthcare, Inc. (ALHC) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial metrics and optimistic guidance, with significant revenue growth and market expansion plans. Despite some concerns over inpatient issues, management has addressed these, and the guidance reflects confidence. The Q&A section indicates that analysts are satisfied with management's responses, and there is optimism about the company's strategic plans, including market expansion and operational efficiency improvements. Given the market cap of approximately $1.5 billion, these positive factors are likely to result in a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Health Plan Membership 284,800 members, representing a year-over-year growth of approximately 31%. This growth was driven by strong execution on sales and retention.
Total Revenue $1.2 billion, which increased 33% year-over-year. The increase was supported by the growth in health plan membership.
Adjusted Gross Profit $146 million, representing an adjusted MBR of 88.2%, which improved by 20 basis points year-over-year. This improvement was underpinned by strong engagement from clinical teams and disciplined execution.
Adjusted SG&A $108 million, which improved as a percentage of revenue by 60 basis points year-over-year to 8.7%. This improvement was supported by scalability initiatives such as back-office automation.
Adjusted EBITDA $38 million, which grew by 88% compared to the prior year. This result exceeded the high end of the guidance range and implies an adjusted EBITDA margin of 3.1%, representing 90 basis points of margin expansion year-over-year.
Operating Cash Flow Strong operating cash flow was generated, concluding with $726 million in cash, cash equivalents, and short-term investments. The funded leverage ratio improved to 2.6x trailing 12-month EBITDA.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Membership Growth: Health plan membership grew by 31% year-over-year to 284,800 members, supporting revenue growth.
Revenue Growth: Revenue increased by 33% year-over-year to $1.2 billion in Q1 2026.
Operational Efficiencies: Adjusted SG&A improved as a percentage of revenue by 60 basis points year-over-year to 8.7%. Claims auto adjudication rate increased from less than 15% to over 60% year-to-date, with further improvements expected.
Technology Investments: Investments in AI-driven contract management and AVA AI risk stratification models are enhancing operational scalability and clinical engagement.
Cost Management: Focused on delivering cost efficiencies through claims automation and improvements in contract management infrastructure.
Strategic Focus on High Acuity Populations: Intentional growth among high acuity populations to leverage the clinical model for better outcomes.
Long-term Scalability: Investments in automation, AI-enabled workflows, and clinical infrastructure to support long-term growth and efficiency.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
CMS Rule Change Impact: The CMS rule change affected the observation determination process, leading to higher inpatient admissions per 1,000 in Q1. Although resolved by February, it created a temporary disruption impacting operational metrics.
Increased Inpatient Admissions: Higher inpatient admissions per 1,000 due to changes in membership mix and CMS rule changes could increase medical costs and strain operational efficiency.
Scalability Challenges: Rapid growth and scaling in a complex Medicare Advantage industry pose challenges in maintaining operational efficiency and achieving growth objectives.
High Acuity Population Growth: Intentional focus on high acuity populations increases the risk of higher medical costs and inpatient admissions, potentially impacting profitability.
Automation and Technology Investments: While automation and AI investments aim to improve efficiency, there is a risk of implementation challenges or delays that could hinder scalability and cost savings.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Health Plan Membership: For the full year 2026, health plan membership is expected to be between 294,000 and 299,000 members. For the second quarter, membership is projected to be between 288,000 and 290,000 members.
Revenue: Full year 2026 revenue is expected to range from $5.16 billion to $5.21 billion, reflecting 31% growth year-over-year. Second quarter revenue is projected to be between $1.30 billion and $1.32 billion.
Adjusted Gross Profit: Full year 2026 adjusted gross profit is expected to be between $620 million and $650 million. For the second quarter, adjusted gross profit is projected to range from $167 million to $177 million.
Adjusted EBITDA: Full year 2026 adjusted EBITDA is expected to range from $138 million to $163 million. Second quarter adjusted EBITDA is projected to be between $50 million and $60 million.
Membership Growth Focus: The company is increasing its membership growth expectations due to strong sales operations and member retention. Growth is focused on high-acuity populations who benefit most from the clinical model.
Profitability Metrics: The low end of adjusted gross profit and adjusted EBITDA guidance ranges has been raised by $5 million, reflecting confidence in achieving full-year objectives.
Inpatient Admissions: Inpatient admissions per 1,000 are expected to run higher year-over-year due to changes in membership mix, focusing on high-acuity populations.
First Half EBITDA Contribution: Approximately 60% of full-year EBITDA is expected to be generated in the first half of 2026, compared to 55% in the first half of 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you explain the hospital observation issue and how it was resolved?
A:The issue was due to paying authorizations at full acute rates instead of observation rates, caused by a workflow problem. It impacted January numbers by a couple of million dollars. The problem was identified and corrected internally, and it is not considered a systemic issue.
Q:What is the expected utilization trend after resolving the hospital observation issue?
A:Utilization is tracking closely to expectations, with admits in the high 150s. Absent the issue, admits would have been in the mid-150s. The flu did not significantly impact the numbers.
Q:What is the outlook for 2Q MBR and year-over-year improvement?
A:The second quarter is expected to show seasonal improvement in MBR. Management expects improvements across all margins, including MBR, SG&A, and EBITDA, in the first half of the year. They are balancing execution and investments in the business.
Q:What are the thoughts on the deferral of a new risk model and its potential implementation?
A:Management believes there will be changes and normalization in the risk model, potentially implemented by 2029. CMS aims to ensure coding is not a competitive advantage and to reward organizations with high quality and low costs.
Q:Can you provide more details on the inpatient issue and its resolution?
A:The issue stemmed from a CMS rule change requiring more timely authorizations. It was related to the de-delegation of certain administrative functions from IPAs. The problem was identified and corrected by February, with workflows now optimized.
Q:What is the impact of new member mix and market growth on inpatient admissions?
A:Growth outside California and in more acute populations led to higher inpatient admissions. This was planned and is aligned with guidance. The growth is primarily in the C-SNP population, which has embedded gross margin opportunities.
Q:How is risk adjustment performing relative to expectations?
A:Risk adjustment for loyal members is predictable, while management takes a cautious stance on new members. Upside opportunities may arise in the second quarter when final sweeps are received.
Q:What is the take on the 2020 RADV audit methodology?
A:The removal of extrapolation methodology in 2020 audits reduces potential financial exposure. Management feels confident about their processes and is not concerned about this area.
Q:Was the inpatient admit issue known during the previous earnings report?
A:Yes, the issue was known and incorporated into guidance. Corrective action was taken quickly, and the first half guidance reflects confidence in performance.
Q:What would MLR have been without the January inpatient issue?
A:MLR would have been approximately 30 basis points lower without the issue.
Q:What is the explanation for the increase in DCPs and reserve methodology?
A:The increase in DCPs includes some Part D components, but the reserve methodology remains consistent and conservative. There is no indication of increased conservatism in reserves.
Q:How is the company approaching the GLP-1 bridge model launch?
A:The company has agreed to participate under certain conditions but has not disclosed specific product strategies for 2027 bids.
Q:What are the plans for new market expansion in 2027?
A:The company plans to expand into new markets, including large ones, but has not disclosed specific locations. They are focused on operational readiness to support growth.
Q:What is the outlook for G&A performance and capital expenditures?
A:G&A performance in the first quarter was strong, but management is cautious about turning it into a full-year beat. Capital expenditures are focused on software development and AI deployment, with a planned spend of $40 million for 2026.
Q:What is the trend in retention and utilization?
A:Retention is tracking well, contributing to membership growth. Utilization trends are consistent and not showing anomalies, with flu and other factors having minimal impact.
Q:What is the rationale for leaning into the PPO product?
A:The decision was based on the ability to stratify members and care for them through the Care Anywhere program. However, management acknowledges challenges in cracking the code for PPO profitability.
Q:How are provider engagement negotiations progressing?
A:Negotiations are progressing well in some markets, but engagement models are critical for expansion decisions. The company is focused on finding the right providers to work with.
Q:What is the perspective on the final rate notice and its implications?
A:Management believes the 2.48% rate increase is below actual trend, which is higher. They are analyzing geographic impacts and preparing market-specific business plans for 2027 bids.
Q:Is there a strategy to bring ancillary benefits in-house?
A:Yes, management is considering bringing ancillary benefits like dental and vision in-house to lower MLR. This could involve acquisitions or starting new services, leveraging the existing member base.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the GLP-1 bridge model launch strategy and 2027 bid tactics, citing competitive reasons. Additionally, they did not disclose specific new market locations for 2027 expansion.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI contract
AI risk
Advantage line
Advantage program
CEO sir
CMS rule
Form measure
Medicare administration
Progress area
Wiser pilot
accountability stakeholder
action accountability
action overutilization
action sustainability
action term
adjudication rate
administration action
administration pursuit
admission end
admission headwind
approach quality
approach scalability
area confidence
aspect people
auto adjudication
automation contract
automation improvement
claim automation
culture
discipline
efficiency
example
infrastructure
month
path
solution
technology
term margin
ALHC Transcript
Alignment Healthcare, Inc. (ALHC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Alignment Healthcare, Inc. (ALHC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Alignment Healthcare, Inc. (ALHC) Q1 2026 Earnings Call Transcript
Positive5-1
The earnings call summary reveals strong financial metrics and optimistic guidance, with significant revenue growth and market expansion plans. Despite some concerns over inpatient issues, management has addressed these, and the guidance reflects confidence. The Q&A section indicates that analysts are satisfied with management's responses, and there is optimism about the company's strategic plans, including market expansion and operational efficiency improvements. Given the market cap of approximately $1.5 billion, these positive factors are likely to result in a stock price increase of 2% to 8% over the next two weeks.
Alignment Healthcare, Inc. (ALHC) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call summary and Q&A indicate strong financial performance with increased EBITDA and revenue, positive free cash flow, and improved operational efficiency. While SG&A increased, it declined as a percentage of revenue. Optimistic guidance and strategic market positioning, including AI investments and strong provider relationships, further support a positive outlook. The company's low exposure to risk model rebasing and proactive approach to regulatory changes enhance confidence. The market cap suggests moderate sensitivity to these positive developments, leading to a likely positive stock price movement over the next two weeks.
ALHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
